PT  - JOURNAL ARTICLE
AU  - Mirjam B Zeisel
AU  - Julie Lucifora
AU  - William S Mason
AU  - Camille Sureau
AU  - Jürgen Beck
AU  - Massimo Levrero
AU  - Michael Kann
AU  - Percy A Knolle
AU  - Monsef Benkirane
AU  - David Durantel
AU  - Marie-Louise Michel
AU  - Brigitte Autran
AU  - François-Loïc Cosset
AU  - Hélène Strick-Marchand
AU  - Christian Trépo
AU  - Jia-Horng Kao
AU  - Fabrice Carrat
AU  - Karine Lacombe
AU  - Raymond F Schinazi
AU  - Françoise Barré-Sinoussi
AU  - Jean-François Delfraissy
AU  - Fabien Zoulim
TI  - Towards an HBV cure: state-of-the-art and unresolved questions—report of the ANRS workshop on HBV cure
AID  - 10.1136/gutjnl-2014-308943
DP  - 2015 Aug 01
TA  - Gut
PG  - 1314--1326
VI  - 64
IP  - 8
4099  - http://gut.bmj.com/content/64/8/1314.short
4100  - http://gut.bmj.com/content/64/8/1314.full
SO  - Gut2015 Aug 01; 64
AB  - HBV infection is a major cause of liver cirrhosis and hepatocellular carcinoma. Although HBV infection can be efficiently prevented by vaccination, and treatments are available, to date there is no reliable cure for the >240 million individuals that are chronically infected worldwide. Current treatments can only achieve viral suppression, and lifelong therapy is needed in the majority of infected persons. In the framework of the French National Agency for Research on AIDS and Viral Hepatitis ‘HBV Cure’ programme, a scientific workshop was held in Paris in June 2014 to define the state-of-the-art and unanswered questions regarding HBV pathobiology, and to develop a concerted strategy towards an HBV cure. This review summarises our current understanding of HBV host-interactions leading to viral persistence, as well as the roadblocks to be overcome to ultimately address unmet medical needs in the treatment of chronic HBV infection.